Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Prostate cancer is the commonest solid-organ cancer diagnosed in males and represents an important source of morbidity and mortality worldwide. Imaging plays a crucial role in diagnosing prostate cancer and informs the ongoing management of the disease at all stages. Several novel molecular imaging technologies have been developed recently that have the potential to revolutionise disease diagnosis and the surveillance of patients living with prostate cancer. These innovations include hyperpolarised MRI, choline PET/CT and PSMA PET/CT. The major utility of choline and PSMA PET/CT currently lies in their sensitivity for detecting early recurrence after radical treatment for prostate cancer and identifying discrete lesions that may be amenable to salvage therapy. Molecular imaging is likely to play a future role in characterising genetic and biochemical signatures in individual tumours, which may be of particular significance as cancer therapies move into an era of precision medicine.

Original publication

DOI

10.1007/s11934-015-0573-z

Type

Journal article

Journal

Curr Urol Rep

Publication Date

03/2016

Volume

17

Keywords

MRI, PET/CT, PSMA, Prostate cancer, Surgery, Animals, Humans, Magnetic Resonance Imaging, Male, Molecular Imaging, Multimodal Imaging, Positron-Emission Tomography, Prostatic Neoplasms, Recurrence, Tomography, X-Ray Computed